Systematic review of 94 studies (84 meta-analysed; 603,827 patients with solid cancers): beta-blocker use was associated with better overall survival (HR 0.88) and progression-free survival (HR 0.82); most studies were observational, with heterogeneity.
Meta-analysisn = 603,827
Eraslan et al. Impact of beta-blockers on prognostic outcomes in solid cancers: a systematic review and meta-analysis